In this episode, we delve into the far-reaching implications of Ozempic, a weight loss drug originally designed for diabetes management, and its potential impact on B2B businesses across various industries. Join us as we explore how this medical breakthrough is reshaping consumer behavior, healthcare trends, and industry dynamics.

Is Your Business the only B2B Immune to Ozempic’s Impact?

I am Tom Spitale, a Partner at Impact Planning Group - welcome to our Podcast!  Along with my colleagues and Partners Mary Abbazia and Sean Welham, we are the authors of "The Accidental Marketer" published by Wiley.  Through our book and our consulting practice, we help (mostly B2B) Accidental Marketers create unique and compelling strategies that differentiate their products and services from the competition.  Our podcast addresses important B2B strategic marketing issues and is designed to help listeners maximize profits in their area of responsibility by creating, communicating and capturing (via pricing strategies) more value for customers than competitors do.

Business

I am Tom Spitale, a Partner at Impact Planning Group - welcome to our Podcast! Along with my colleagues and Partners Mary Abbazia and Sean Welham, we are the authors of "The Accidental Marketer" published by Wiley. Through our book and our consulting practice, we help (mostly B2B) Accidental Marketers create unique and compelling strategies that differentiate their products and services from the competition. Our podcast addresses important B2B strategic marketing issues and is designed to help listeners maximize profits in their area of responsibility by creating, communicating and capturing (via pricing strategies) more value for customers than competitors do.

Share Is Your Business the only B2B Immune to Ozempic’s Impact?

Sign up to save your podcasts

Is Your Business the only B2B Immune to Ozempic’s Impact?

Is Your Business the only B2B Immune to Ozempic’s Impact?